

Syntheses, Anti-tumor Activities and Toxicities of Platinum(II) Complexes Containing Piperidine and Morpholine Derivatives

T. SOLIN, K. MATSUMOTO* and K. FUWA

Department of Chemistry, Faculty of Science, University of Tokyo, Hongo, Bunkyo-ku, Tokyo 113, Japan

Received June 17, 1982

Since the discovery of Rosenberg *et al.* that *cis*-Pt(NH₃)₂Cl₂ exhibits anti-tumor activity [1], numerous complexes with the general formula, *cis*-PtA₂X₂ (A = amine, X = halogen), have been synthesized and tested for anti-tumor activity. Various kinds of amines have been used as ligands and attempts have been made to find out the relation between the structure of the amine ligand and the anti-tumor activity [2]. One of the tendencies discovered was that when A was varied from cyclopropylamine to cyclooctylamine increasing the carbon ring size gradually, the anti-tumor activity was maximal at cyclohexylamine [3]. Cyclopentylamine also exhibits high activity but all other amines are only slightly active. The fact that the cyclohexyl ring is advantageous for anti-tumor activity is also exhibited by the markedly high activity of Pt(1,2-cyclohexanediamine)Cl₂ [4-7]. In this paper we report the syntheses, anti-tumor activities and acute toxicities of platinum complexes containing N-(2-aminoethyl)

piperidine (aep) and N-(2-aminoethyl)morpholine (aem), Pt(aep)X₂ and Pt(aem)X₂ (X = halogen). These ligands are also one of the saturated six-membered ring compounds but the ring contains nitrogen (aep) and oxygen (aem), respectively.

Experimental

As the complexes, Pt(aem)X₂, were prepared in a manner similar to that of Pt(aep)X₂, the preparations of Pt(aep)X₂ (X = Cl, Br, I) are given as examples. Infrared spectra (400-4000 cm⁻¹) in KBr pellets were recorded with a Hitachi 260-30 spectrometer and those of far infrared were recorded with a Hitachi EPI-L spectrometer. Platinum concentrations were measured with a Shimadzu atomic absorption spectrophotometer AA 640-13 equipped with a graphite furnace atomizer, Shimadzu GFA-3.

Synthesis of Pt(aep)I₂

Four grams of KI and 1 mmol of K₂PtCl₄ were dissolved in 20 ml of water, which resulted in a solution of 0.05 M in PtI₄²⁻ and 1 M in I⁻. To the solution, 1 mmol of aep was added and a yellow precipitate of Pt(aep)I₂ immediately appeared. The precipitate was filtered, washed with water and ethanol, and then air-dried.

Syntheses of Pt(aep)Cl₂ and Pt(aep)Br₂

Two mmol of AgNO₃ was added to 1 mmol of Pt(aep)I₂ suspended in 20 ml of water. The suspension was stirred overnight in the dark and the resulting precipitate of AgI was removed by centrifugation and filtration. About 20 times equivalent of NaCl was added to the filtrate and Pt(aep)Cl₂

*Author to whom correspondence should be addressed.

TABLE I. Elemental Analyses of Pt(aep)X₂ and Pt(aem)X₂.

Complex		%C	%H	%N	%X	%Pt
Pt(aep)Cl ₂	found	21.19	4.14	7.26	18.02	50.1
	calcd	21.33	4.09	7.11	17.99	49.49
Pt(aep)Br ₂	found	17.24	3.43	5.83	32.71	42.6
	calcd	17.40	3.34	5.80	33.08	40.38
Pt(aep)I ₂	found	14.41	2.87	4.87	43.54	34.4
	calcd	14.57	2.79	4.85	43.98	33.80
Pt(aem)Cl ₂	found	18.00	3.76	7.11	17.59	49.7
	calcd	18.19	3.56	7.07	17.90	49.24
Pt(aem)Br ₂	found	14.73	3.04	5.75	32.69	38.9
	calcd	14.86	2.91	5.77	32.94	40.22
Pt(aem)I ₂	found	12.30	2.48	4.80	43.55	33.8
	calcd	12.44	2.44	4.84	43.83	33.69

TABLE II. Far Infrared Absorptions due to Pt-halogen Stretching Observed in Pt(aep)X₂ and Pt(aem)X₂.

Complex	Pt-X (cm ⁻¹)
Pt(aep)Cl ₂	332 s, 316 vs
Pt(aep)Br ₂	231 vs, 213 vs
Pt(aem)Cl ₂	362 s, 320 vs
Pt(aem)Br ₂	241 s, 213 vs

was precipitated. Pt(aep)Br₂ was obtained in a similar manner, where instead of NaCl, NaBr was added to the filtrate.

Procedure for Studies of Anti-tumor Activity

Complexes were suspended in water and administered i.p. to CDF₁ mice. The activity is expressed as T/C (%), the ratio of survival days for treated and untreated mice. Each of the treated and the untreated groups consisted of six mice and the tumor used was L1210.

Results and Discussion

Elemental analyses of the complexes synthesized are given in Table I. All the complexes are yellow and are insoluble in water and most organic solvents. The yields of the complexes are. Pt(aep)Cl₂ 72.0%, Pt(aep)Br₂ 53.2%, Pt(aep)I₂ 96.0%, Pt(aem)Cl₂ 76.0%, Pt(aem)Br₂ 66.1%, Pt(aem)I₂ 96.4%. Although Pt(aep)Cl₂ and Pt(aem)Cl₂ can be synthesized directly from the reaction of K₂PtCl₄ and the amine ligands, the yields are markedly decreased to 25% with this procedure.

Infrared and far infrared spectra of each compound indicate two distinct absorption bands around 200 ~ 300 cm⁻¹, due to Pt-X stretching modes. These bands are tabulated in Table II. The fact that each compound shows two absorption bands due to Pt-X stretching confirms *cis* configuration of the two halogens. Absorptions of Pt-I stretching could not be measured, since they lie in a 170 ~ 180 cm⁻¹ region.

The results of the studies on the anti-tumor activities are shown in Table III, as well as LD₅₀s. Pt(aep)Cl₂ and Pt(aem)Cl₂ exhibit appreciably high activity, and the activity decreases as the ligand X goes from Cl to I in both amine series. Table III indicates that the toxicity also decreases as X changes from Cl to I.

TABLE III. Results of Preliminary Screening of Pt(aep)X₂ and Pt(aem)X₂ against L1210 and their LD₅₀s.

Complex	best dose (mg/kg)	T/C (%)	T/C (%)
Pt(aep)Cl ₂	50	195	75
Pt(aep)Br ₂	50	151	150
Pt(aep)I ₂	25	127	100
Pt(aem)Cl ₂	50	188	125
Pt(aem)Br ₂	50	125	150
Pt(aem)I ₂	50	117	200
<i>cis</i> -Pt(NH ₃) ₂ Cl ₂	12.5	278 ⁸	13 ⁹

The present result indicates that although the activities of Pt(aep)X₂ and Pt(aem)X₂ are slightly less than that of *cis*-Pt(NH₃)₂Cl₂, they are less toxic than the latter. This fact encourages a further survey of six-membered heteroring compounds as amine ligands in order to reduce the nephro toxicity, which is presently the most serious problem with anti-tumor platinum complexes.

Acknowledgement

The authors are indebted to Dr. T. Tashiro for conducting the screening test of the present compounds. Thanks are also due to Dr. N. Nakamura of Kyowa Hakko Kogyo Co., for carrying out the toxicity test. This work has been financially supported by Japanese Ministry of Health and Welfare.

References

- 1 B. Rosenberg, L. VanCamp, J. E. Trasko and V. H. Mansour, *Nature* 222, 385 (1969).
- 2 M. J. Clare and J. D. Hoeschele, *Biomorg. Chem.*, 2, 187 (1973).
- 3 M. J. Clare, P. C. Hydes, B. W. Malerby and D. M. Watkins, *Biochimie*, 60, 835 (1978).
- 4 T. A. Connors, M. Jones, W. C. J. Ross, P. D. Braddock, A. R. Khokhar and M. L. Tobe, *Chem. Biol Interactions*, 5, 415 (1972).
- 5 M. J. Cleare and J. D. Hoeschele, *Platinum Metals Rev.*, 17, 2 (1973).
- 6 Y. Kidani, K. Inagaki and S. Tsukagoshi, *Gann*, 67, 923 (1976).
- 7 Y. Kidani, K. Inagaki, R. Saita and S. Tsukagoshi, *J Clin Hematol. Oncol.*, 7, 197 (1977).
- 8 Y. Kidani, K. Inagaki and S. Tsukagoshi, *Gann*, 67, 921 (1976).
- 9 T. A. Connors and J. J. Roberts, Eds., 'Platinum Coordination Complexes in Cancer Chemotherapy', Recent Results Cancer Res., Vol. 48, Springer-Verlag (1974).